Single Centre, Randomised, Single-Blind, Pilot Study to Compare the Safety, Tolerability and Pharmacokinetics of AVT02 to EU-approved Humira as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adult Subjects (ALVOPAD)
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2019
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Acronyms ALVOPAD
- Sponsors Alvotech
- 17 Jan 2019 Status changed from active, no longer recruiting to completed.
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2018 New trial record